Literature DB >> 26977017

Knockdown of EPHA1 by CRISPR/CAS9 Promotes Adhesion and Motility of HRT18 Colorectal Carcinoma Cells.

B O Wu1, Wen G Jiang2, Deshan Zhou3, Yu-Xin Cui4.   

Abstract

BACKGROUND: Erythropoietin-producing hepatocellular A1 (EPHA1) is the first member of the EPH superfamily. Its abnormal expression has been reported in various cancer types. However, the contribution of EPHA1 to the regulation of colorectal cancer cell behaviour remains unknown.
MATERIALS AND METHODS: In this study, we investigated the expression profile of EPHA1 in human colorectal cancer and its effect on the adhesion and motility of colorectal cancer cells. We used human colorectal cancer specimens and the colorectal adenocarcinoma cell line HRT18 for this purpose.
RESULTS: Our cohort screening data showed that in patients with colorectal cancer, low expression of EPHA1 gene is correlated with a remarkably reduced survival. After EPHA1 is knocked-down in colorectal cancer cells using a clustered regularly interspaced short palindromic repeats-associated nuclease 9 (CRISPR-CAS9) genomic editing system, we observed an increase in the spreading and adhesion of HRT18 cells. Moreover, protein array data indicated that the extracellular-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) signaling pathways were activated as a consequence. Inhibition of ERK and JNK proteins with specific inhibitors led to suppression of migration of the colorectal cancer cells.
CONCLUSION: EPHA1 suppresses spreading and adhesion of HRT18 colorectal cancer cells through deactivation of ERK and JNK signaling pathways. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CAS9; CRISPR; EPHA1; adhesion; colorectal carcinoma cells; motility

Mesh:

Substances:

Year:  2016        PMID: 26977017

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  EphB3 Stimulates Cell Migration and Metastasis in a Kinase-dependent Manner through Vav2-Rho GTPase Axis in Papillary Thyroid Cancer.

Authors:  Jing-Jing Li; Zhi-Jian Sun; Yan-Mei Yuan; Fen-Fen Yin; Yao-Gang Bian; Ling-Yun Long; Xue-Li Zhang; Dong Xie
Journal:  J Biol Chem       Date:  2016-12-16       Impact factor: 5.157

Review 2.  CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Authors:  Fatima Akram; Ikram Ul Haq; Sania Sahreen; Narmeen Nasir; Waqas Naseem; Memoona Imitaz; Amna Aqeel
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 3.  Therapeutic gene editing: delivery and regulatory perspectives.

Authors:  Gayong Shim; Dongyoon Kim; Gyu Thae Park; Hyerim Jin; Soo-Kyung Suh; Yu-Kyoung Oh
Journal:  Acta Pharmacol Sin       Date:  2017-04-10       Impact factor: 6.150

4.  A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers.

Authors:  Julia Rudno-Rudzińska; Wojciech Kielan; Ewelina Frejlich; Krzysztof Kotulski; Wojciech Hap; Krzysztof Kurnol; Przemysław Dzierżek; Marcin Zawadzki; Agnieszka Hałoń
Journal:  Chin J Cancer Res       Date:  2017-08       Impact factor: 5.087

Review 5.  Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.

Authors:  Chung-Ting Jimmy Kou; Raj P Kandpal
Journal:  Biomed Res Int       Date:  2018-02-28       Impact factor: 3.411

6.  A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

Authors:  Alexandre de Nonneville; Pascal Finetti; José Adelaide; Éric Lambaudie; Patrice Viens; Anthony Gonçalves; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639

7.  OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.

Authors:  Chengcheng Hao; Yuxin Cui; Siyuan Chang; Jing Huang; Emily Birkin; Mu Hu; Xiuyi Zhi; Wenbin Li; Lijian Zhang; Shan Cheng; Wen G Jiang
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.